Vivek Panwar
VIDWAN ID: 662962

Dr Vivek Panwar

Male Doctor of Philosophy
Assistant Professor | Chitkara School of Pharmacy
Chitkara University, Kalu Jhanda (Barotiwala), Solan
Himachal Pradesh
Expertise: Medicinal Chemistry
11 Publications
0 Projects
1005 Scopus Citations
966 CrossRef
1 Year 11 Months Total Experience
Publications
11 Total
Articles
4
Chapters
7
Activity

No publication activity to display.

Scopus Scopus
1,005 Citations
4 h-index
CrossRef CrossRef
966 Citations
4 h-index
Google Scholar Google Scholar

Loading Scholar statistics...

Professional Recognition

No Data Found

There is currently nothing to display here.

Community & Membership

No Data Found

There is currently nothing to display here.

Association of Pharmacy Professionals
life time member
Jan 2023

Personal Details

Doctor of Philosophy
2024
N/A
Assistant Professor
Oct 2024 – Present
Chitkara University, Kalu Jhanda (Barotiwala), Solan | Chitkara School of Pharmacy
Medical and Health Sciences
Medicinal Chemistry

Related Profiles

Scholarly Work

No Data Found

There is currently nothing to display here.

No Data Found

There is currently nothing to display here.

No Data Found

There is currently nothing to display here.

Scholarly Publications

Molecular medicine and biomedical research in the era of precision medicine: New technologies, lifestyle interventions and personalized drug therapies for patient care

Book Chapter
Year: 2025. Pages: xxxi-l .
Authors: R.C. Sobti; Vivek Panwar; Deepak Kumar

Recent advances in mammalian target of rapamycin targeted heterocyclic scaffolds as anticancer agents

Book Chapter
Year: 2025. Pages: 339-351 .
Authors: Vivek Panwar; Manjunath Ghate; Raj Kumar; Deepak Kumar

EGFR-Targeted Quinazoline Clubbed Heterocycles as Anticancer Agents

Book Chapter
Year: 2022. Pages: 387-399 .
Authors: Vivek Panwar; Kritika Mukherji; Manjunath Ghate; Deepak K. Jindal; Deepak Kumar

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

Open Access
Journal Article
Signal Transduction and Targeted Therapy. Year: 2023. Volume: 8 , Issue: 1 , Pages: 375 .
Authors: Vivek Panwar; Aishwarya Singh; Manini Bhatt; Rajiv K. Tonk; Shavkatjon Azizov; Agha Saquib Raza; Shinjinee Sengupta; Deepak Kumar; Manoj Garg

Design, synthesis, in silico, anticancer evaluations of N-acylhydrazone derivatives as STAT3 inhibitors

Journal Article
Future Medicinal Chemistry. Year: 2025. Volume: 17 , Issue: 13 , Pages: 1509-1519 .
Authors: Vivek Panwar; Yajat Rohila; Aishwarya Singh; Meenakshi; Bhavana Singh; Manoj K Gupta; Manoj Garg; Deepak Kumar

Synthesis, Evaluation and Docking Studies of Disubstituted N‐Heterocyclic Derivatives as Anticancer Agents

Journal Article
CHEMISTRY & BIODIVERSITY. Year: 2024. Volume: 21 , Issue: 12 , Pages: e202401010 .
Authors: Sreenivasulu Reddy Gopireddy; Vivek Panwar; Ankan Sarkar; Manish Jain; Kothapalli Bannoth Tejaswini; Kothapalli Bannoth Chandrasekhar; Deepak Kumar

Transition metal complexes of triazole-based bioactive ligands: synthesis, spectral characterization, antimicrobial, anticancer and molecular docking studies

Open Access
Journal Article
Research on Chemical Intermediates. Year: 2022. Volume: 48 , Issue: 2 , Pages: 703-729 .
Authors: Deswal, Y.; Asija, S.; Kumar, D.; Jindal, D.K.; Chandan, G.; Panwar, V.; Saroya, S.; Kumar, N.

Recent advances in FDA-approved kinase inhibitors targeting lung cancer

Book Chapter
Year: 2024. Pages: 1277-1287 .
Authors: Vivek Panwar; Manini Bhatt; Dheeraj Bisht; Rajeshwar K. K. Arya; Deepak Kumar
Showing 1 to 8 of 11 publications